[go: up one dir, main page]

WO2008019061A3 - Anticorps monoclonaux anti-il-6 et leurs utilisations - Google Patents

Anticorps monoclonaux anti-il-6 et leurs utilisations Download PDF

Info

Publication number
WO2008019061A3
WO2008019061A3 PCT/US2007/017337 US2007017337W WO2008019061A3 WO 2008019061 A3 WO2008019061 A3 WO 2008019061A3 US 2007017337 W US2007017337 W US 2007017337W WO 2008019061 A3 WO2008019061 A3 WO 2008019061A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
amino acid
well
region selected
acid variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/017337
Other languages
English (en)
Other versions
WO2008019061A2 (fr
Inventor
Ernest S Smith
Wei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR20097003512A priority Critical patent/KR101479537B1/ko
Priority to JP2009522880A priority patent/JP2009545319A/ja
Priority to MX2009001110A priority patent/MX2009001110A/es
Priority to CA2657763A priority patent/CA2657763C/fr
Priority to CN2007800289537A priority patent/CN101563365B/zh
Priority to BRPI0715115-2A priority patent/BRPI0715115A2/pt
Priority to EP07811042.6A priority patent/EP2064241B1/fr
Priority to AU2007282023A priority patent/AU2007282023B2/en
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Priority to EA200900037A priority patent/EA200900037A1/ru
Publication of WO2008019061A2 publication Critical patent/WO2008019061A2/fr
Publication of WO2008019061A3 publication Critical patent/WO2008019061A3/fr
Priority to NO20090224A priority patent/NO20090224L/no
Priority to IL196550A priority patent/IL196550A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne de nouveaux anticorps monoclonaux qui se lient spécifiquement à l'IL-6. Les anticorps de l'invention comportent une région variable de chaîne lourde (VH) choisie parmi n'importe laquelle des régions VH décrites dans ce document aussi bien que des variants d'acide aminé de celles-ci, et/ou une région variable de chaîne légère (VL) choisie parmi n'importe laquelle des régions VL décrites dans ce document aussi bien que des variants d'acide aminé de celles-ci. L'invention concerne également des procédés de traitement de maladies et de troubles associés à l'expression et/ou l'activité de IL-6.
PCT/US2007/017337 2006-08-03 2007-08-03 Anticorps monoclonaux anti-il-6 et leurs utilisations Ceased WO2008019061A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP07811042.6A EP2064241B1 (fr) 2006-08-03 2007-08-03 Anticorps monoclonaux anti-il-6 et leurs utilisations
MX2009001110A MX2009001110A (es) 2006-08-03 2007-08-03 Anticuerpos monoclonales anti-il-6 y usos de los mismos.
CA2657763A CA2657763C (fr) 2006-08-03 2007-08-03 Anticorps monoclonaux anti-il-6 et leurs utilisations
CN2007800289537A CN101563365B (zh) 2006-08-03 2007-08-03 抗-il-6单克隆抗体及其用途
BRPI0715115-2A BRPI0715115A2 (pt) 2006-08-03 2007-08-03 anticorpo monoclonal isolado, molÉcula de Ácido nucleico isolada, vetor de expressço, cÉlula hospedeira, mÉtodos para tratar uma doenÇa, e para produzir um anticorpo monoclonal isolado, uso do anticorpo monoclonal isolado, e, composiÇço farmacÊutica
AU2007282023A AU2007282023B2 (en) 2006-08-03 2007-08-03 Anti-IL-6 monoclonal antibodies and uses thereof
EA200900037A EA200900037A1 (ru) 2006-08-03 2007-08-03 Моноклональные антитела против интерлейкина-6 (il-6) и их применение
KR20097003512A KR101479537B1 (ko) 2006-08-03 2007-08-03 항-ｉｌ-6 모노클로날 항체 및 이의 용도
JP2009522880A JP2009545319A (ja) 2006-08-03 2007-08-03 抗ｉｌ−６モノクローナル抗体およびその使用
NO20090224A NO20090224L (no) 2006-08-03 2009-01-15 Anti-IL-6 monoklonale antistoffer og anvendelser derav
IL196550A IL196550A0 (en) 2006-08-03 2009-01-15 Anti-il-6 monoclonal antibodies and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83510706P 2006-08-03 2006-08-03
US60/835,107 2006-08-03

Publications (2)

Publication Number Publication Date
WO2008019061A2 WO2008019061A2 (fr) 2008-02-14
WO2008019061A3 true WO2008019061A3 (fr) 2008-10-09

Family

ID=39033490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/017337 Ceased WO2008019061A2 (fr) 2006-08-03 2007-08-03 Anticorps monoclonaux anti-il-6 et leurs utilisations

Country Status (17)

Country Link
US (1) US7919095B2 (fr)
EP (1) EP2064241B1 (fr)
JP (1) JP2009545319A (fr)
KR (1) KR101479537B1 (fr)
CN (1) CN101563365B (fr)
AU (1) AU2007282023B2 (fr)
BR (1) BRPI0715115A2 (fr)
CA (1) CA2657763C (fr)
CO (1) CO6150192A2 (fr)
CR (1) CR10563A (fr)
EA (1) EA200900037A1 (fr)
IL (1) IL196550A0 (fr)
MA (1) MA30653B1 (fr)
MX (1) MX2009001110A (fr)
NO (1) NO20090224L (fr)
WO (1) WO2008019061A2 (fr)
ZA (1) ZA200900514B (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
KR101829776B1 (ko) 2007-05-21 2018-02-19 앨더바이오 홀딩스 엘엘씨 Ｉｌ-６에 대한 항체 및 이의 용도
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
CN102089326B (zh) 2008-05-13 2014-12-31 诺维莫尼公司 抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2010036851A2 (fr) * 2008-09-26 2010-04-01 Wyeth Llc Conception d'une banque d'anticorps simple chaîne
CN102245207B (zh) * 2008-11-13 2015-11-25 费塔制药股份有限公司 人源化抗il-6抗体
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8337847B2 (en) * 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
JP5832291B2 (ja) 2008-11-25 2015-12-16 アルダーバイオ ホールディングス エルエルシー 血栓症を予防または治療するためのｉｌ−６のアンタゴニスト
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8911722B2 (en) 2009-09-14 2014-12-16 The Regents Of The University Of Colorado, A Body Corporate Modulation of yeast-based immunotherapy products and responses
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066369A2 (fr) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonistes de l'il-6 destinés à faire augmenter l'albumine et/ou à faire baisser la crp
SG10201501803YA (en) 2010-03-12 2015-05-28 Immunogen Inc Cd37-binding molecules and immunoconjugates thereof
ES2847891T3 (es) 2010-11-23 2021-08-04 Vitaeris Inc Anticuerpos anti-IL-6 para el tratamiento de la mucositis oral
WO2012098238A1 (fr) 2011-01-21 2012-07-26 Novimmune S.A. Associations thérapeutiques et méthodes d'utilisation d'agents modulateurs anti-cd3 et d'antagonistes anti-il-6
MX2013011385A (es) 2011-04-01 2014-03-13 Immunogen Inc Moleculas de union a cd37 y sus inmunoconjugados.
WO2013175276A1 (fr) * 2012-05-23 2013-11-28 Argen-X B.V Molécules se liant à l'il-6
TWI500629B (zh) 2012-10-22 2015-09-21 Fountain Biopharma Inc 介白素－６抗體及其用途
WO2014074905A1 (fr) * 2012-11-08 2014-05-15 Eleven Biotherapeutics, Inc. Antagonistes de l'il-6 et leurs utilisations
WO2016200676A1 (fr) 2015-06-08 2016-12-15 Immunogen, Inc. Combinaisons d'immunoconjugués anti-cd37 et d'anticorps anti-cd20
CA2991637C (fr) 2015-07-31 2022-07-05 Medimmune Limited Methodes de traitement de troubles medies par l'hepcidine
CN108699144B (zh) 2015-08-28 2022-07-19 德彪发姆国际有限公司 用于检测cd37的抗体和测定
JP2019506863A (ja) * 2016-02-02 2019-03-14 カドモン コーポレイション，リミティド ライアビリティ カンパニー Ｐｄ−ｌ１及びｋｄｒに対する二重結合タンパク質
WO2017192933A1 (fr) * 2016-05-05 2017-11-09 Weiner, David Anticorps monoclonaux anti-adn ciblant l'il-6 et le cd126
JP2020510608A (ja) 2016-11-02 2020-04-09 デビオファーム インターナショナル， エス． アー． 抗ｃｄ３７イムノコンジュゲート療法を改善するための方法
TW202444416A (zh) 2017-02-01 2024-11-16 耶魯大學 心臟衰竭及心腎症候群之精準治療
MY201934A (en) 2018-01-05 2024-03-25 Novo Nordisk As Methods for treating il-6 mediated inflammation without immunosuppression
CN112218662A (zh) 2018-05-30 2021-01-12 德彪发姆国际有限公司 抗cd37免疫缀合物给药方案
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
JP2022537555A (ja) 2019-06-20 2022-08-26 武田薬品工業株式会社 ウイルスベースの遺伝子療法による治療方法
CN112279913B (zh) * 2020-10-30 2022-05-03 上海百英生物科技有限公司 一种抗人il-6单克隆抗体及应用
WO2022115705A2 (fr) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Évaluation non invasive de la maladie d'alzheimer
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN115925792B (zh) * 2022-08-19 2025-06-27 浙江农林大学 一种香榧活性肽及其在制备降血压产品中的应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312996A2 (fr) * 1987-10-19 1989-04-26 Kishimoto, Tadamitsu, Prof. Anticorps monoclonal contre le bcdf humain
EP0399429A1 (fr) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anticorps monoclonal contre l'interleukine-6 humaine
EP0410813A1 (fr) * 1989-07-28 1991-01-30 Fujirebio Inc. Anticorps monoclonal contre le BCDF humain et immuno-analyse l'utilisant
DE3939706C1 (fr) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
WO2004039826A1 (fr) * 2001-11-14 2004-05-13 Centocor, Inc. Anticorps anti-il-6, compositions, methodes et utilisations associees
EP1536012A1 (fr) * 2002-08-30 2005-06-01 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Anticorps d'interleukine-6 antihumaine de type humain et fragment de l'anticorps
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL88375A (en) 1988-11-14 1995-07-31 Yeda Res & Dev Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
WO1990005144A1 (fr) 1988-11-11 1990-05-17 Medical Research Council Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
JPH03139292A (ja) * 1989-05-22 1991-06-13 Toray Ind Inc ヒトインタ―ロイキン―６に対するモノクロ―ナル抗体
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
JP3614183B2 (ja) * 1993-05-31 2005-01-26 中外製薬株式会社 ヒトインターロイキン−６に対する再構成ヒト抗体
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US6083501A (en) 1994-06-07 2000-07-04 Toray Industries, Inc. Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases
EP0783893B1 (fr) 1994-10-07 2012-04-04 Chugai Seiyaku Kabushiki Kaisha Inhibition de la croissance anormale de cellules synoviales a l' aide d' un antagoniste d'interleukine 6 comme principe actif
ATE214602T1 (de) 1994-12-29 2002-04-15 Chugai Pharmaceutical Co Ltd Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten
GB9702944D0 (en) 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
WO1998042377A1 (fr) 1997-03-21 1998-10-01 Chugai Seiyaku Kabushiki Kaisha Substances servant a la prevention ou au traitement de maladies liees a la cellule-t sensibilisee contenant comme principe actif des antagonistes de l'il-6
PL201461B1 (pl) 1998-03-17 2009-04-30 Chugai Pharmaceutical Co Ltd Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny
US7494652B1 (en) 1998-06-10 2009-02-24 Promega Corporation Treatment of sepsis
CA2341239C (fr) 1998-08-24 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Agent preventif ou therapeutique de la pancreatite comprenant un antagoniste de l'il-6 en tant qu'ingredient actif
US7083950B2 (en) 1998-09-25 2006-08-01 Regeneron Pharmaceuticals, Inc. High affinity fusion proteins and therapeutic and diagnostic methods for use
JP2003525862A (ja) 1999-01-27 2003-09-02 ザ ユニヴァーシティー オブ サウス フロリダ ヒト癌の治療のためのｓｔａｔ３シグナル伝達の阻害
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
JP2003531867A (ja) 2000-05-03 2003-10-28 メディミューン，インコーポレイテッド 抗体および抗炎症薬を用いた呼吸器疾患の組合せ治療法
EP1334731B1 (fr) 2000-10-25 2008-02-27 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002036165A1 (fr) 2000-10-27 2002-05-10 Chugai Seiyaku Kabushiki Kaisha Agent à base d'antagoniste d'il-6, faisant baisser le niveau des mmp-3 dans le sang
DE60126130T2 (de) 2000-11-17 2007-10-18 The University Of Rochester In-vitro verfahren zur herstellung und identifizierung von immunglobulin moleküle in eukaryotischen zellen
WO2002069904A2 (fr) 2001-03-02 2002-09-12 Medimmune, Inc. Prevention ou traitement de maladies inflammatoires ou auto-immunes par administration d'antagonistes de cd2 en combinaison avec d'autres agents prophylactiques ou therapeutiques
WO2002070007A1 (fr) 2001-03-02 2002-09-12 Medimmune, Inc. Prevention ou traitement de troubles inflammatoires ou auto-immuns par l'administration d'antagonistes de l'integrine $g(a)v$g(b)¿3?
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
AU2002360068B2 (en) 2001-12-21 2009-09-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Method for cloning of variable domain sequences
US20060275294A1 (en) 2002-08-22 2006-12-07 Omoigui Osemwota S Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer
EP1572103A4 (fr) 2002-11-15 2008-02-13 Centocor Inc Utilisations anti-angiogeniques d'antagonistes de il-6
US20040161426A1 (en) 2003-02-04 2004-08-19 Mohit Trikha Use of IL-6 antagonists in combination with steroids to enhance apoptosis
EP1444989A1 (fr) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensibilisation de cellules à l'apoptose par bloquage selective de cytokines
NZ541928A (en) 2003-02-24 2009-06-26 Chugai Pharmaceutical Co Ltd Remedy for spinal injury containing interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2005023193A2 (fr) 2003-09-04 2005-03-17 Interleukin Genetics, Inc. Methodes permettant de traiter l'endometriose
US20050095246A1 (en) 2003-10-24 2005-05-05 Medtronic, Inc. Techniques to treat neurological disorders by attenuating the production of pro-inflammatory mediators
US20050100550A1 (en) 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
JP2008505054A (ja) 2004-02-11 2008-02-21 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー Ｉｌ−６アンタゴニストで骨関節炎を治療する方法
KR20070095949A (ko) 2004-12-16 2007-10-01 제넨테크, 인크. 자가면역 장애의 치료 방법
US20060228416A1 (en) 2005-04-06 2006-10-12 Marie-Pierre Faure Methods for modulating topical inflammatory response
EP1712241A1 (fr) 2005-04-15 2006-10-18 Centre National De La Recherche Scientifique (Cnrs) Composition pour application intratumorale dans le traitement du cancer
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
EP2377884A1 (fr) 2005-05-10 2011-10-19 Neoloch Aps Peptides neuritogènes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312996A2 (fr) * 1987-10-19 1989-04-26 Kishimoto, Tadamitsu, Prof. Anticorps monoclonal contre le bcdf humain
EP0399429A1 (fr) * 1989-05-22 1990-11-28 Toray Industries, Inc. Anticorps monoclonal contre l'interleukine-6 humaine
EP0410813A1 (fr) * 1989-07-28 1991-01-30 Fujirebio Inc. Anticorps monoclonal contre le BCDF humain et immuno-analyse l'utilisant
DE3939706C1 (fr) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
US5856135A (en) * 1993-05-31 1999-01-05 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
WO2004039826A1 (fr) * 2001-11-14 2004-05-13 Centocor, Inc. Anticorps anti-il-6, compositions, methodes et utilisations associees
EP1536012A1 (fr) * 2002-08-30 2005-06-01 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Anticorps d'interleukine-6 antihumaine de type humain et fragment de l'anticorps

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SHIMAMURA T ET AL: "ANALYSIS OF INTERLEUKIN 6 (IL-6)/IL-6 RECEPTOR SYSTEM USING MONOCLONAL ANTI-IL-6 ANTIBODIES", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 11, 1 November 1991 (1991-11-01), pages 1155 - 1161, XP000764448, ISSN: 0161-5890 *
WIJDENES J ET AL: "Human recombinant dimeric il-6 binds to its receptor as detected by anti-il-6 monoclonal antibodies", MOLECULAR IMMUNOLOGY, ELMSFORD, NY, US, vol. 28, no. 11, 1 January 1991 (1991-01-01), pages 1183 - 1192, XP002974189, ISSN: 0161-5890 *

Also Published As

Publication number Publication date
ZA200900514B (en) 2010-04-28
KR20090039801A (ko) 2009-04-22
CO6150192A2 (es) 2010-04-20
JP2009545319A (ja) 2009-12-24
AU2007282023A1 (en) 2008-02-14
US7919095B2 (en) 2011-04-05
EA200900037A1 (ru) 2009-10-30
CA2657763A1 (fr) 2008-02-14
NO20090224L (no) 2009-03-31
KR101479537B1 (ko) 2015-01-07
CN101563365B (zh) 2012-10-31
IL196550A0 (en) 2011-08-01
MX2009001110A (es) 2009-05-11
CN101563365A (zh) 2009-10-21
MA30653B1 (fr) 2009-08-03
AU2007282023B2 (en) 2012-09-13
EP2064241A2 (fr) 2009-06-03
US20080075726A1 (en) 2008-03-27
EP2064241B1 (fr) 2015-10-07
CA2657763C (fr) 2016-05-31
CR10563A (es) 2009-04-14
BRPI0715115A2 (pt) 2013-06-04
WO2008019061A2 (fr) 2008-02-14

Similar Documents

Publication Publication Date Title
WO2008019061A3 (fr) Anticorps monoclonaux anti-il-6 et leurs utilisations
WO2008079246A3 (fr) Anticorps anti-cd44
WO2007024846A3 (fr) Anticorps anti-il-23
WO2007137984A3 (fr) Immunoglobulines
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2006114704A3 (fr) Anticorps de la p-cadherine
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
TW200722518A (en) Sc(fv)2 structural isomers
WO2006096489A3 (fr) Compositions d'anticorps anti-m-csf a niveaux d'endotoxine reduits
WO2007113172A3 (fr) Anticorps
NZ595235A (en) Compositions and methods for increasing muscle growth
WO2010021697A3 (fr) Anticorps anti-ccr2
WO2010017103A3 (fr) Anticorps monoclonaux anti-nkg2d humain entièrement humains
WO2007058823A3 (fr) Anticorps anti-egfr
UA95478C2 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО, КОТОРОЕ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТ с-Kit
GEP20104887B (en) Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
WO2007143168A3 (fr) Anticorps dirigés contre le récepteur de l'il-6 humaine, à affinité élevée pour ledit récepteur
WO2009071696A3 (fr) Molécules d'anticorps humanisés spécifiques pour il-31
WO2009048537A3 (fr) Anticorps humanisé
NZ594682A (en) Fully human antibodies specific to cadm1
WO2007068750A3 (fr) Immunoglobulines
WO2007003421A3 (fr) Immunoglobulines
WO2007007159A3 (fr) Anticorps anti-madcam servant a traiter des troubles uterins

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780028953.7

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2657763

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009522880

Country of ref document: JP

Ref document number: CR2009-010563

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007282023

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200900037

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 574282

Country of ref document: NZ

Ref document number: 272/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009010128

Country of ref document: EG

Ref document number: 09007783

Country of ref document: CO

Ref document number: MX/A/2009/001110

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12009500227

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007282023

Country of ref document: AU

Date of ref document: 20070803

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097003512

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: DZP2009000114

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2007811042

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07811042

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0715115

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090129